BioSpace News Archive

Pharm Country

Latest Research Evaluating Clinical Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the European Society of Cardiology (ESC) Congress

Amarin Corporation plc (NASDAQ:AMRN) today announced the acceptance of funded research for presentation at the European Society of Cardiology (ESC) Congress, both onsite and online in Amsterdam, August 25-28, 2023.

July 26, 2023
·
11 min read
Drug Development

PharmAbcine Announces First Patient Dosed in the Phase I Clinical Trial of Its Novel TIE2 Agonistic Antibody in nAMD

PharmAbcine Inc. announced today that the first patient has been dosed in the Phase I clinical trial of PMC-403, the Company’s novel TIE2 agonistic antibody, in nAMD (neovascular age-related macular degeneration).

July 26, 2023
·
4 min read
Drug Development

CoImmune Announces Publication of Preclinical Results with SEAKER Cells in Solid Tumor Melanomas

CoImmune, Inc. today announced the publication of preclinical results with Synthetic Enzyme-Armed Killer (SEAKER) cells in solid tumor melanomas in the peer-reviewed journal Cancer Immunology Research.

July 26, 2023
·
3 min read
FDA

Octapharma’s Prothrombin Complex Concentrate, Balfaxar®, Receives FDA Approval For Warfarin Reversal in Urgent Surgery & Invasive Procedures

Octapharma USA today announced that Balfaxar ® (prothrombin complex concentrate, human-lans; marketed in Europe and Canada as octaplex ® ) has received U.S. Food and Drug Administration (FDA) approval for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist (VKA, e.g., warfarin) therapy in adult patients with need for urgent surgery or invasive procedures.

July 26, 2023
·
5 min read
Drug Development

Viage Therapeutics announces data from a Phase 1 study with DGX-001, a first-in-class oral neurotherapeutic targeting cognitive impairment in patients with Alzheimer’s Disease and Parkinson’s Disease

Viage Therapeutics (Viage), a neuroscience company based on a platform of novel neurotherapeutics, today announced positive findings from its Phase 1 study of DGX-001, a first-in class oral therapeutic targeting the AVPR1A receptor in the gut.

July 26, 2023
·
3 min read
Drug Development

SKYRIZI® (risankizumab) Achieved Superiority Versus Apremilast for Co-Primary Endpoints Among Adult Patients with Moderate Plaque Psoriasis in Phase 4 Head-to-Head Study

AbbVie (NYSE: ABBV) today announced the British Journal of Dermatology published results from the head-to-head Phase 4 IMMpulse study that evaluated the efficacy and safety of SKYRIZI® (risankizumab) compared to Otezla® (apremilast) among adult patients with moderate plaque psoriasis eligible for systemic therapy.1

July 26, 2023
·
12 min read
Business

ExThera Medical in Growth Mode after FDA Approval of Investigational Device Exemption

ExThera Medical Corporation today announces the addition of Michael DiMeo as Chief Financial Officer.

July 26, 2023
·
5 min read
Genetown

Nexo Therapeutics Launches With $60 Million Series A Financing

Nexo Therapeutics today emerged from stealth with a $60 million Series A financing.

July 26, 2023
·
8 min read
Pharm Country

Quantum-Si to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Quantum-Si Incorporated today announced that it will be participating in the Canaccord Genuity 43rd Annual Growth Conference taking place at the InterContinental Boston Hotel on August 7-10, 2023.

July 26, 2023
·
1 min read
Genetown

Arsenal Medical Announces Treatment of First Patient with NeoCast™

Arsenal Medical today announced enrollment of the first patient with the company’s investigational NeoCast™ embolic biomaterial.

July 26, 2023
·
2 min read